Real-world efficacy of Lenvatinib/Pembrolizumab combination in anaplastic thyroid carcinoma: case series from two Italian referral centers - PubMed
5 hours ago
- #Lenvatinib Pembrolizumab Combination
- #Anaplastic Thyroid Carcinoma
- #Real-world Efficacy
- The study evaluated the real-world efficacy of Lenvatinib plus Pembrolizumab (L+P) in 16 patients with anaplastic thyroid carcinoma (ATC), an aggressive cancer.
- Results showed a median overall survival of 10 months and median progression-free survival of 6 months, with an objective response rate of 37.5% and disease control rate of 68.8%.
- A baseline CONUT score ≤ 2 was significantly associated with longer overall survival and progression-free survival, identifying it as a prognostic factor for response to therapy.